<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharma on Timey.org</title>
    <link>https://timey.org/tags/pharma/</link>
    <description>Recent content in Pharma on Timey.org</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 24 Apr 2026 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://timey.org/tags/pharma/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AbbVie to Build $1.4 Billion AI-Integrated Manufacturing Campus in North Carolina</title>
      <link>https://timey.org/abbvie-to-build-1.4-billion-ai-integrated-manufacturing-campus-in-north-carolina/</link>
      <pubDate>Fri, 24 Apr 2026 00:00:00 +0000</pubDate>
      <guid>https://timey.org/abbvie-to-build-1.4-billion-ai-integrated-manufacturing-campus-in-north-carolina/</guid>
      <description>AbbVie has selected North Carolina as the site for a new $1.4 billion manufacturing campus that will integrate artificial intelligence with advanced production and laboratory technologies to support its immunology, neuroscience, and oncology medicine lines. No timeline for completion was announced.&#xA;The investment reflects both the scale of AbbVie&amp;rsquo;s pipeline ambitions and a broader pharmaceutical industry trend toward AI-assisted manufacturing—applying machine learning to process optimization, quality control, and yield prediction in ways that reduce variability and regulatory risk.</description>
    </item>
    <item>
      <title>Eli Lilly to Acquire Kelonia Therapeutics, Expanding In Vivo CAR-T Cell Therapy Capabilities</title>
      <link>https://timey.org/eli-lilly-to-acquire-kelonia-therapeutics-expanding-in-vivo-car-t-cell-therapy-capabilities/</link>
      <pubDate>Fri, 24 Apr 2026 00:00:00 +0000</pubDate>
      <guid>https://timey.org/eli-lilly-to-acquire-kelonia-therapeutics-expanding-in-vivo-car-t-cell-therapy-capabilities/</guid>
      <description>Eli Lilly has announced a deal to acquire Kelonia Therapeutics, gaining access to KLN-1010, a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 trials for relapsed or refractory multiple myeloma, with data recently featured at the 2025 ASH Annual Meeting plenary session. The acquisition also brings Kelonia&amp;rsquo;s in vivo gene delivery and integration platform, which Lilly views as broadly applicable across its genetic medicine programs.&#xA;The distinction between in vivo and ex vivo CAR-T is significant.</description>
    </item>
  </channel>
</rss>
